400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
ChiCTR2500104716
尚未开始
/
/
/
2025-06-23
/
/
Glaucoma
A novel deep learning-based three-dimensional retinal vascular analysis for progression risk stratification in glaucoma patients
A novel deep learning-based three-dimensional retinal vascular analysis for progression risk stratification in glaucoma patients
Aim 1 • To develop a novel deep learning-based 3D model for retinal vasculature analysis in glaucoma patients. Aim 2 • To integrate the novel biomarkers of our proposed 3D DL retinal vasculature system with clinical biomarkers for the establishment of a risk stratification model of glaucoma progression.
诊断试验诊断准确性
其它
NA
/
Health and Medical Research Fund
/
/
/
2025-07-01
2027-04-30
/
1. Older than 18 years 2. Best corrected visual acuity (BCVA) no less than 20/40. 3. No severe systemic disorders (i.e., those without clinical retinal involvement). 4. Glaucoma is defined when at least one eye had the presence of the structural and functional evidence of glaucoma, including glaucomatous optic disc cupping, RNFL damage, or neuroretinal rim loss, and minimal criteria for glaucomatous VF defect as per published standard (38): glaucoma hemifield test result outside normal limits, pattern standard deviation (PSD) with P < 0.05 or a cluster of 3 or more points in the pattern deviation plot in a single hemifield with P < 0.05, one of which must have P < 0.01. Any one of the preceding criteria, if repeatable, was considered sufficient evidence for the glaucomatous visual field (VF) defect.;
请登录查看1. Other ocular diseases that may cause retinal vascular change, such as diabetic retinopathy, hypertension retinopathy; or AMD. 2. Extremely myopia (i.e., axial length > 27.0 mm). 3. OCTA images with insufficient image quality.;
请登录查看The Chinese University of Hong Kong
/
BioArt2026-01-16
药明康德2026-01-16
GLP1减重宝典2026-01-15
温江高新区2026-01-15
良医汇肿瘤资讯2026-01-15
氨基观察2026-01-15
Juventas合源生物2026-01-15
医药速览2026-01-15
CPHI制药在线2026-01-15
CPHI制药在线2026-01-15